Amgen Presents New Phase 2 Data On IMLYGIC ® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017

First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor Data Demonstrate IMLYGIC in Combination With YERVOY® (Ipilimumab) Doubled Objective Response Rate in Unresectable Advanced Melanoma Responses Not Limited to Injected Lesions; 50 Percent or Higher Reduction in Visceral Lesion Size Occurred More Frequently in Patients in the Combination Arm THOUSAND OAKS, Calif., June 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with the immune checkpoint inhibitor YERVOY® (ipilimumab)* more than doubled objective r...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news